Datopotamab Deruxtecan-dlnk
Datopotamab deruxtecan-dlnk is a type of targeted therapy drug called an antibody–drug conjugate. It consists of a monoclonal antibody linked to a toxic drug called deruxtecan that binds to a protein on the surface of some cancer cells. The linked drug enters these cancer cells and blocks an enzyme called topoisomerase I. This damages the DNA of the cancer cells and kills them.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Datopotamab deruxtecan-dlnk is approved to treat adults with:
- Breast cancer. It is used in patients whose cancer has spread to other parts of the body or cannot be removed by surgery, including:
- hormone receptor positive (HR+) and HER2 negative (HER2-) cancer in patients who have received hormone therapy and chemotherapy
- triple-negative breast cancer (TNBC) in patients who cannot receive PD-1 or PD-L1 inhibitor therapy
- Non-small cell lung cancer that has an abnormal EGFR gene. It is used in patients who have received EGFR-targeted therapy and platinum chemotherapy for cancer that has spread.¹
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that datopotamab deruxtecan-dlnk provides a clinical benefit in these patients.
Datopotamab deruxtecan-dlnk is also being studied in the treatment of other types of cancer.
More About Datopotamab Deruxtecan-dlnk
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Datopotamab Deruxtecan-dlnk - A lay language summary of important information about this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Datopotamab Deruxtecan-dlnk - Check for trials from NCI's list of cancer clinical trials now accepting patients.